Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Tax Provisions (2020 - 2026)

Ironwood Pharmaceuticals' Tax Provisions history spans 8 years, with the latest figure at -$38.1 million for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 275.37% to -$38.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 92.06% decrease, with the full-year FY2025 number at $5.2 million, down 91.9% from a year prior.
  • Tax Provisions hit -$38.1 million in Q4 2025 for Ironwood Pharmaceuticals, down from $27.9 million in the prior quarter.
  • Over the last five years, Tax Provisions for IRWD hit a ceiling of $27.9 million in Q3 2025 and a floor of -$336.9 million in Q2 2021.
  • Historically, Tax Provisions has averaged -$11.8 million across 5 years, with a median of $13.5 million in 2023.
  • The widest YoY moves for Tax Provisions: up 4325.0% in 2022, down 963.35% in 2022.
  • Tracing IRWD's Tax Provisions over 5 years: stood at $4.9 million in 2021, then plummeted by 963.35% to -$42.4 million in 2022, then grew by 4.55% to -$40.5 million in 2023, then surged by 153.7% to $21.7 million in 2024, then crashed by 275.37% to -$38.1 million in 2025.
  • Business Quant data shows Tax Provisions for IRWD at -$38.1 million in Q4 2025, $27.9 million in Q3 2025, and $14.2 million in Q2 2025.